Lifeward logo

Lifeward

Lifeward, formerly ReWalk Robotics, is a maker of the ReWalk personal exoskeleton and AlterG anti-gravity rehabilitation systems, founded in 2001 and based in Hudson, Massachusetts, and Yokneam Illit, Israel. Medicare pays $91,032 for a personal exoskeleton.5,2

Robotics Reviewed Editorial TeamUpdated November 2, 2026golifeward.com

Our take

Lifeward sells the ReWalk, the first exoskeleton cleared by the FDA for personal use, along with AlterG anti-gravity treadmills for clinics. Its pricing is unusually visible for medical robotics because Medicare set a lump-sum fee of $91,032 for personal exoskeletons in 2024, and Aetna, Humana, and UnitedHealthcare added Medicare Advantage coverage in 2025.5,2,6

The business is small and in flux. Revenue fell 14% to $22.0 million in 2025, the company lost $19.9 million, and it agreed to a deal that could give Oramed up to 49.99% of its shares. Second-quarter 2026 revenue rose 16% to $6.6 million, and Josh Hexter took over as interim CEO in September 2026.2,3,4

Scores by criterion

Lifeward scores out of 10
Pricing transparency6.0
Product maturity8.0
Deployment evidence7.0
Company durability4.6
Ease of integration6.0
Overall score (average of the five)6.3

Each criterion is defined on our methodology page.

Who uses Lifeward and what it's for

The ReWalk Personal Exoskeleton serves people with spinal cord injury who want to stand and walk at home and in the community, and is often bought through Medicare, the Veterans Health Administration, or private insurers. AlterG systems serve rehabilitation clinics, sports teams, and hospitals.5,2

Lifeward sells directly in the United States and through a mix of direct sales and distributors in Germany, Canada, and Australia.5

ReWalk, AlterG, and ReStore

ReWalk uses tilt sensors, an onboard computer, and motorized legs to let people with paraplegia stand and walk. The FDA cleared stair and curb use in 2023, and ReWalk 7 is the newest model.5,1

Lifeward bought AlterG in August 2023 for about $19 million. AlterG treadmills use NASA-derived differential air pressure to reduce body weight during rehabilitation and are used in more than 4,000 facilities in more than 40 countries. Lifeward also sells the ReStore soft exo-suit for stroke and distributes MYOLYN FES cycles.5

Finances and the Oramed deal

2025 revenue was $22.0 million, down from $25.7 million, with ReWalk sales of $8.5 million. Net loss narrowed to $19.9 million, and the company ended the year with $2.2 million in unrestricted cash.2

Shareholders approved a deal with Oramed Pharmaceuticals under which Lifeward acquires Oramed's oral protein delivery technology and Oramed can own up to 49.99% of Lifeward. Lifeward had $9.4 million in cash at June 30, 2026.2,3

Competitive landscape

Which of these companies scores best, and who is each one built for?Hover over or tap a logo for details.
Top rated, for patients and clinicsTop rated, for large hospitalsLower score, for patients and clinicsLower score, for large hospitalsNot yet reviewed45678910Review Score← Patients and clinicsLarge hospital systems →Who it's built for6.35.97.06.6
Lifeward and its competitors
CompanyProductPricing modelDeployment footprintWhere Lifeward wins or loses
LifewardReWalk personal exoskeleton and AlterG anti-gravity systems2Medicare fee of $91,032 for a personal exoskeleton5Individual users through Medicare and insurers; AlterG in more than 4,000 facilities5Personal use with an established Medicare fee; small, loss-making company
Ekso BionicsEksoNR exoskeleton for gait training after stroke and brain injury10Not published10Inpatient rehabilitation facilities; first exoskeleton FDA-cleared for stroke10Lifeward wins on personal use at home with a Medicare fee. Ekso wins in inpatient rehabilitation for stroke.
WandercraftEve self-balancing personal exoskeleton and Atalante X for clinics12,11Not published12More than 150 clinical centers; acquired Ekso Bionics in 202612,13Lifeward wins on a longer record and a Medicare fee. Wandercraft wins on hands-free, self-balancing walking.
MyomoMyoPro powered arm and hand brace22Medicare fee schedule rates of $33,481 and $65,87215Patients reached through clinician referrals and orthotics and prosthetics channels16,23Lifeward wins on walking for people with spinal cord injury. Myomo wins on arm and hand function.
Saebo (SaeboFlex)Non-powered dynamic hand splint with springs that reopen the hand18Not published; custom-fit by a trained professional18Outpatient clinics and rehabilitation facilities18Lifeward wins on powered walking. Saebo wins on low-cost hand rehabilitation.
CyberdyneMedical HAL wearable robot driven by the wearer's bioelectric signals19Not published; mainly rentals and treatment services20Approvals or certifications in more than 20 countries24Lifeward wins on a personal device with a Medicare fee. Cyberdyne wins on clinic treatment across more indications.

Limits

Cash is tight. The company has relied on financing deals and the Oramed transaction to fund operations.2,3

Leadership changed in 2026. Mark Grant left as CEO and Josh Hexter is interim CEO.4 Rami Aviram, named CFO in August, withdrew before starting, and Ronen Tsimerman has been CFO since November 1, 2026.8,9

The new oral drug delivery business is unrelated to robotics and may pull attention from the core rehabilitation products.2

Rivals are consolidating. Wandercraft acquired Ekso Bionics on October 1, 2026, putting two of Lifeward's exoskeleton competitors under one owner. See our Wandercraft review.7

What customers say

Where it helps

Coverage is the main help for patients. Medicare has a fee schedule for personal exoskeletons, and Medicare Advantage coverage from Aetna, Humana, and UnitedHealthcare reaches about 16 million covered lives, according to Lifeward.5,2

Where it falls short

We found no independent customer reviews. The concerns in public filings are financial: a revenue decline in 2025, continued losses, and dependence on outside financing.2

Where customer reviews couldn't be found, our analysts attempted to give a voice to buyer sentiment, drawing on real information from review sites, forums and product documentation. Based on: Lifeward SEC filings, earnings releases, and website.

Leadership

  • Josh Hexter

    Josh Hexter

    Interim chief executive officer

    Hexter became interim CEO on September 1, 2026. He was previously chief operating and business officer of Oramed Pharmaceuticals and chief business officer of BrainsWay.4

    Read full profile

  • Ronen Tsimerman

    Ronen Tsimerman

    Chief financial officer

    Tsimerman became CFO on November 1, 2026, after serving as CFO of IceCure Medical from 2017 to 2026. Rami Aviram, named to the role in August, withdrew before starting.9,8

  • Avi Gabay

    Chairman

    Gabay is chairman of Lifeward's board.4

Sources

  1. Lifeward, Homepage, accessed November 2, 2026
  2. Lifeward, Lifeward reports fourth quarter and full year 2025 financial results, March 18, 2026, accessed November 2, 2026
  3. Lifeward, Lifeward reports strong second quarter 2026 financial results, August 14, 2026, accessed November 2, 2026
  4. Lifeward, Lifeward appoints Josh Hexter interim chief executive officer, August 31, 2026, accessed November 2, 2026
  5. Lifeward, Form 10-Q for the quarter ended September 30, 2024, accessed November 2, 2026
  6. Wikipedia, ReWalk, accessed November 2, 2026
  7. Wandercraft, Wandercraft acquires Ekso Bionics, October 1, 2026, accessed November 2, 2026
  8. Lifeward, Form 8-K, October 8, 2026, accessed November 2, 2026
  9. Lifeward, Form 8-K, October 27, 2026, accessed November 2, 2026
  10. Ekso Bionics, EksoNR, accessed November 1, 2026
  11. Wandercraft, Atalante X, accessed November 1, 2026
  12. Wandercraft, Eve personal exoskeleton, accessed November 1, 2026
  13. Wandercraft, Wandercraft acquires Ekso Bionics, accessed November 1, 2026
  14. Myomo, About Myomo, accessed November 1, 2026
  15. Myomo, CMS posts final Medicare DMEPOS fee schedule rate for the MyoPro, March 1, 2024, accessed October 31, 2026
  16. Myomo, Second quarter 2026 results, SEC exhibit 99.1, August 5, 2026, accessed October 31, 2026
  17. Saebo, Home page, accessed November 1, 2026
  18. Saebo, SaeboFlex, accessed November 1, 2026
  19. Cyberdyne, Medical HAL lower limb type, accessed November 2, 2026
  20. Cyberdyne, Financial results briefing for the fiscal year ended March 31, 2026, May 14, 2026, accessed November 3, 2026
  21. Cyberdyne, Consolidated financial results for the fiscal year ended March 31, 2026, May 14, 2026, accessed November 3, 2026
  22. Myomo, Homepage, accessed October 31, 2026
  23. Myomo, Fourth quarter and full year 2025 results, accessed October 31, 2026
  24. Cyberdyne, About Cyberdyne, accessed November 3, 2026